Improved Survival Amongst Patients Treated With Adjuvant Tamoxifen After Mastectomy for Early Breast Cancer

Baum, Michael; Dossett, J. A.; Patterson, J.S.; Smiddy, F. G.; Wilson, A. J.; Richards, Donald A.; Brinkley, Diana; McPherson, Klim; Rubens, Robert; Stoll, Basil A.; Lea, J.; Ellis, Sidra

doi:10.1016/s0140-6736(83)90406-3

Cited by 103 publications

(45 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This downward trend can be attributed to treatment and screening programs. Since the 1980s there have been continuous advancements in treatment, such as the use of adjuvant therapy to reduce the risk of BC recurrence [31], new chemotherapy drugs to slow cancer growth [32], and the introduction of sentinel-lymphnode biopsy to assess BC spread [33]. Currently, clinicians approach this disease with a rapidly evolving multidisciplinary treatment [34].…”

Section: Discussionmentioning

confidence: 99%

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Martín‐Sánchez

Clèries

Lidón

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the main cause of cancer mortality among women, and mortality from lung cancer (LC) is increasing among women. The purpose of the present study was to project the mortality rates of both cancers and predict when LC mortality will exceed BC mortality. Methods: The cancer mortality data and female population distribution were obtained from the Spanish National Statistics Institute. Crude rate (CR), age-standardized rate (ASR), and age-specific rate were calculated for the period 1980-2013 and projected for the period 2014-2020 using a Bayesian log-linear Poisson model. Results: All calculated rates were greater for BC than for LC in 2013 (CR, 27.3 versus 17.3; ASR, 13.5 versus 9.3), and the CR was not projected to change by 2020 (29.2 versus 27.6). The ASR for LC is expected to surpass that of BC in 2019 (12.9 versus 12.7). Conclusions: By 2020 the LC mortality rates may exceed those of BC for ages 55-74 years, possibly because of the prevalence of smoking among women, and the screening for and more effective treatment of BC. BC screening could be a good opportunity to help smokers quit by offering counseling and behavioral intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Martín‐Sánchez

Clèries

Lidón

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

“…The results from randomized studies in the 1970s changed the treatment of early stage breast cancer and established adjuvant tamoxifen therapy for ER-positive breast cancer [20,27,28]. However the importance of ER status as a predictor was not completely established until 1990 [29].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

Khoshnoud

Löfdahl

Fohlin

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early stage invasive breast cancer. Patients and methodsThe Stockholm Breast Cancer Study Group conducted a randomized trial during 1976 through 1990 comparing adjuvant tamoxifen versus control. The patients were stratified according to tumor size and lymph node status in high risk and low risk groups. In this study we evaluated 683 patients with "low risk" breast cancer (size≤30 mm, lymph node-negative) for whom ER status had been determined by both the cytosol assays and immunohistochemistry at one pathology laboratory. The median follow up was 17 years. ResultSix hundred eighty three patients had tumors with ER determined by both methods, 536 (78.5%) were ERpositive by cytosol assays using the cut off level at ≥ 0.05 fmol/µg DNA and 539 patients were ER-positive ConclusionBoth IHC and cytosol assay accurately predict long-term response to adjuvant tamoxifen.3

show abstract

“…Early results from controlled trials initiated during the 1970s which became available during the early to mid 1980s laid the foundation for this treatment policy [3,18,19]. The Stockholm adjuvant TAM trial was one of those studies.…”

Section: Discussionmentioning

confidence: 99%

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

2007

View full text Add to dashboard Cite

Improved Survival Amongst Patients Treated With Adjuvant Tamoxifen After Mastectomy for Early Breast Cancer

Cited by 103 publications

References 3 publications

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

Contact Info

Product

Resources

About